Genentech’s Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine

Posted on by sHq_LoGiNz

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $RHHBY–evERA results published in The New England Journal of Medicine underscore the potential of investigational giredestrant in ER+ advanced breast cancer.

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.